Magenta Therapeutics
Cambridge
About Magenta Therapeutics
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $405.9M
- Funding stage: M&A
- Last round: Post-IPO Equity (May 2021)
- Ticker: nasdaq:MGTA
- Website: magentatx.com
- Phone: 857.242.0170
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/magenta-therapeutics-2242993 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.